Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA6 | P23280 | 5/20 | 0.55 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | CA5A | P35218 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11871853 | 0.93 | CYP2C19 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL30607521 | 0.93 | CYP2C19 (0.56) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL8987400 | 0.91 | CA12 (0.50) | CA12CA6CA7CA9CA14 | |
| SCHEMBL323463 | 0.90 | CYP2C19 (0.58) | CA12CA6CA7CA9CA14 | |
| SCHEMBL4562850 | 0.88 | PAOX (0.53) | CA12CA6CA7CA9CA14 | |
| SCHEMBL28327427 | 0.87 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL15746957 | 0.87 | CYP2C19 (0.50) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10123951 | 0.85 | CYP2C19 (0.58) | CA12CA6CA7CA9CA14 | |
| SCHEMBL14451145 | 0.85 | CYP2C19 (0.48) | CA12CA6CA7CA9CA14 | |
| SCHEMBL10123895 | 0.84 | CYP2C19 (0.52) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192239-A1 | ANTI-MICROBIAL COMPOSITION | Byotrol PLC (GB) | 2023-06-14 | — | — | EP | disclosed |
| EP-2797413-B1 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2018-09-12 | — | — | EP | disclosed |
| US-9814688-B2 | Antimicrobial compositions and methods for their use | DERMCARE-VET PTY LTD (AU) | 2017-11-14 | — | — | US | disclosed |
| US-20170165208-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE-VET PTY LTD (AU) | 2017-06-15 | — | — | US | disclosed |
| US-9555015-B2 | Antimicrobial compositions and methods for their use | DERMCARE-VET PTY LTD (AU) | 2017-01-31 | — | — | US | disclosed |
| EP-2797413-A1 | ANTI-MICROBIAL COMPOSITION | Byotrol PLC (GB) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013098547-A1 | ANTI-MICROBIAL COMPOSITION | BYOTROL PLC (GB) | 2013-07-04 | — | — | WO | disclosed |
| EP-1755576-B1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE VET PTY LTD (AU) | 2011-07-13 | — | — | EP | disclosed |
| EP-1755576-A4 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE VET PTY LTD (AU) | 2009-07-08 | — | — | EP | disclosed |
| US-20070282008-A1 | Antimicrobial Compositions and Methods for Their Use | DEMCARE-VET PTY LTD (AU) | 2007-12-06 | — | — | US | disclosed |
| EP-1755576-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE-VET PTY LTD (AU) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005097094-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | DERMCARE-VET PTY LTD (AU) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165208-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THEIR USE | CUTA, PUF60, UNG | CA12 965/4885CA6 467/4885CA7 199/4885 |
| US-20070282008-A1 | Antimicrobial Compositions and Methods for Their Use | CUTA, PUF60, UNG | CA12 965/4885CA6 467/4885CA7 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.